Using specific immune cells to develop new treatments for HIV
Harnessing CD89+ NK Cells for Novel Therapeutic Interventions Against HIV/SIV
This study is looking at a special type of immune cell called CD89+ natural killer cells to see how they help fight HIV, with the hope of finding new ways to improve treatment for people living with the virus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10937151 on NIH RePORTER |
What this research studies
This research investigates the role of CD89+ natural killer (NK) cells in the immune response to HIV infection. By examining how these cells function and their potential as a therapeutic target, the study aims to uncover new strategies for treating HIV. The researchers will analyze samples from both humans and nonhuman primates to understand the unique characteristics of CD89+ NK cells and their interactions within the immune system. This approach may lead to innovative interventions that enhance the body's ability to combat HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are seeking new treatment options beyond standard antiretroviral therapy.
Not a fit: Patients who are not infected with HIV or those who are not responsive to immune-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve the immune response against HIV, potentially offering better management or even a cure for the infection.
How similar studies have performed: While the approach of targeting NK cells is relatively novel, preliminary research has shown promising results in understanding their role in HIV infection.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Reeves, Roger Keith — Duke University
- Study coordinator: Reeves, Roger Keith
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.